Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in Relapsed or Refractory B-Cell Lymphoma and Leukemia
NCT06678282Phase 1Recruiting
- Sponsor
- Genocury Biotech
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in B cell lymphoma and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Genocury Biotech. Primary endpoints: Incidence of adverse events at 24 months and Maximum Tolerated Dose at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
JY231
03
Conditions
B cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06678282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678282.